Lupus nephritis in children: a longitudinal study of prognostic factors and therapy
- PMID: 8793802
- DOI: 10.1681/ASN.V76924
Lupus nephritis in children: a longitudinal study of prognostic factors and therapy
Abstract
There are only a few studies in the pediatric literature that have analyzed risk factors for renal failure in childhood lupus nephritis. This study reviewed the outcome of 56 children (4 to 18 yr of age) with lupus nephritis seen at the authors' institution over a 27-yr period (1965 to 1992), in relation to risk factors and therapy. All children underwent percutaneous renal biopsy before the institution of therapy. From 1965 to 1987, treatment for Class III and IV lupus nephritis consisted of high-dose pulse methylprednisolone, 500 mg daily for 10 days, followed by oral prednisone. From 1987 to 1992, IV cyclophosphamide was given monthly for 6 months and then every 3 months for a period of 3 yr for patients with Class III and Class IV disease. Of 56 children, 42% had Class IV and 21% had Class III histology at onset. The mean follow-up period was 4 yr and ranged from 0.5 to 20.3 yr. Life-table analysis showed that the cumulative proportion of patients surviving was 82.8% at 5 yr and 67.7% at 10 yr. Renal survival was 44.4% at 5 yr and 29% at 10 yr, after the initial diagnosis of lupus nephritis was made. Age at diagnosis, race, sex, initial serum creatinine level, and the presence of proteinuria, hypertension, and DNA antibody titers were reviewed with respect to disease progression, as was the histological class at diagnosis. The effect of the different therapies was also examined. Univariate analysis revealed a significant association of progression to ESRD with an elevated serum creatinine level (P = 0.021), decreased C3 complement (P = 0.024), hypertension (P = 0.053), and histological classification of Class IV lupus nephritis (P = 0.031). Multivariate analysis demonstrated that progression to ESRD was independently associated with an initial Class IV histology (relative risk, 1.78; P < 0.003), hypertension at presentation (relative risk, 1.67; P < 0.003), and a low C3 complement level in conjuction with a high creatinine level (relative risk, 1.52; P < 0.028). Among children with lupus nephritis, those with Class IV disease, hypertension, high creatinine levels, and low C3 complement levels at the time of diagnosis are at increased risk for ESRD. Initial histological classification of lupus nephritis was the most reliable prognostic factor for disease progression. This study was unable to detect a difference in outcome for the two treatment groups.
Similar articles
-
Lupus nephritis in children: prognostic significance of clinicopathological findings.Nephron. 2001 Feb;87(2):118-26. doi: 10.1159/000045899. Nephron. 2001. PMID: 11244305
-
Longterm followup of childhood lupus nephritis.J Rheumatol. 2002 Dec;29(12):2635-42. J Rheumatol. 2002. PMID: 12465165
-
Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.Rheumatol Int. 2009 Jul;29(9):1057-67. doi: 10.1007/s00296-009-0905-8. Epub 2009 Apr 21. Rheumatol Int. 2009. PMID: 19381639
-
Treatment of lupus nephritis in children.Pediatr Nephrol. 2000 Feb;14(2):158-66. doi: 10.1007/s004670050034. Pediatr Nephrol. 2000. PMID: 10684369 Review.
-
The course and treatment of lupus nephritis.Annu Rev Med. 1994;45:525-37. doi: 10.1146/annurev.med.45.1.525. Annu Rev Med. 1994. PMID: 8198400 Review.
Cited by
-
Treatment options for juvenile-onset systemic lupus erythematosus.Paediatr Drugs. 2002;4(4):241-56. doi: 10.2165/00128072-200204040-00004. Paediatr Drugs. 2002. PMID: 11960513 Review.
-
Retrospective analysis of the renal outcome of pediatric lupus nephritis.Clin Rheumatol. 2004 Aug;23(4):318-23. doi: 10.1007/s10067-004-0919-2. Epub 2004 Jun 2. Clin Rheumatol. 2004. PMID: 15293092
-
The human glomerular endothelial cells are potent pro-inflammatory contributors in an in vitro model of lupus nephritis.Sci Rep. 2019 Jun 6;9(1):8348. doi: 10.1038/s41598-019-44868-y. Sci Rep. 2019. PMID: 31171837 Free PMC article.
-
Presentation and outcome of paediatric membranous non-proliferative lupus nephritis.Pediatr Nephrol. 2015 Jan;30(1):113-21. doi: 10.1007/s00467-014-2908-2. Epub 2014 Jul 31. Pediatr Nephrol. 2015. PMID: 25080370
-
Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study.Clin Exp Nephrol. 2016 Aug;20(4):628-636. doi: 10.1007/s10157-015-1171-6. Epub 2015 Oct 20. Clin Exp Nephrol. 2016. PMID: 26482578
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous